JP2012521360A - Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 - Google Patents

Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 Download PDF

Info

Publication number
JP2012521360A
JP2012521360A JP2012501020A JP2012501020A JP2012521360A JP 2012521360 A JP2012521360 A JP 2012521360A JP 2012501020 A JP2012501020 A JP 2012501020A JP 2012501020 A JP2012501020 A JP 2012501020A JP 2012521360 A JP2012521360 A JP 2012521360A
Authority
JP
Japan
Prior art keywords
composition
amino acid
ala
lys
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012501020A
Other languages
English (en)
Japanese (ja)
Inventor
サリバン，ジヨン・ケイ
ミランダ，レスリー・ピー
ゲツグ，コリン・ブイ
フー，シヨウ−フエン・シルビア
ベロウスキ，エドワード・ジエイ
マレー，ジヤステイン・ケイ
グエン，ハン
ウオーカー，ケネス・ダブリユ
アローラ，タルナ
ジエイコブセン，フレデリツク・ダブリユ
リー，ユエ−シユヨン
ブーン，トーマス・シー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2012521360A publication Critical patent/JP2012521360A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/66—Thymopoietins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
JP2012501020A 2009-03-20 2010-03-19 Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 Pending JP2012521360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21059409P 2009-03-20 2009-03-20
US61/210,594 2009-03-20
PCT/US2010/028061 WO2010108154A2 (en) 2009-03-20 2010-03-19 Selective and potent peptide inhibitors of kv1.3

Publications (1)

Publication Number Publication Date
JP2012521360A true JP2012521360A (ja) 2012-09-13

Family

ID=42740266

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012501020A Pending JP2012521360A (ja) 2009-03-20 2010-03-19 Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
JP2012501019A Pending JP2012521197A (ja) 2009-03-20 2010-03-19 担体免疫グロブリンおよびその使用
JP2015001336A Active JP6173359B2 (ja) 2009-03-20 2015-01-07 担体免疫グロブリンおよびその使用
JP2017077334A Active JP6345832B2 (ja) 2009-03-20 2017-04-10 担体免疫グロブリンおよびその使用
JP2018097620A Active JP6609347B2 (ja) 2009-03-20 2018-05-22 担体免疫グロブリンおよびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012501019A Pending JP2012521197A (ja) 2009-03-20 2010-03-19 担体免疫グロブリンおよびその使用
JP2015001336A Active JP6173359B2 (ja) 2009-03-20 2015-01-07 担体免疫グロブリンおよびその使用
JP2017077334A Active JP6345832B2 (ja) 2009-03-20 2017-04-10 担体免疫グロブリンおよびその使用
JP2018097620A Active JP6609347B2 (ja) 2009-03-20 2018-05-22 担体免疫グロブリンおよびその使用

Country Status (7)

Country Link
US (5) US20120121591A1 (enExample)
EP (3) EP2408814B1 (enExample)
JP (5) JP2012521360A (enExample)
AU (2) AU2010226392B9 (enExample)
CA (4) CA2889453C (enExample)
MX (4) MX2011009798A (enExample)
WO (2) WO2010108154A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505639A (ja) * 2013-01-25 2016-02-25 ヤンセン バイオテツク，インコーポレーテツド Ｋｖ１．３アンタゴニスト及び使用方法
WO2018135598A1 (ja) * 2017-01-19 2018-07-26 国立大学法人 東京大学 新規蛍光標識方法
JP2018521062A (ja) * 2015-06-29 2018-08-02 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
JP2023019170A (ja) * 2021-07-28 2023-02-09 株式会社三協 錠剤用崩壊剤及びこれを利用した錠剤

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
SG189769A1 (en) 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN103339145A (zh) * 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
KR20140038501A (ko) 2011-06-06 2014-03-28 키네타 원, 엘엘씨 Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
AU2012270366C1 (en) 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
MX2014014894A (es) * 2012-06-04 2015-02-20 Irm Llc Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
US10066019B2 (en) 2012-10-12 2018-09-04 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
NZ739063A (en) * 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
US10344060B2 (en) * 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9708377B2 (en) 2013-10-28 2017-07-18 Monash University Scorpion toxin analogue and method for treating autoimmune diseases
AU2014373593B2 (en) * 2013-12-23 2020-07-16 Zymeworks Bc Inc. Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
WO2015188132A1 (en) * 2014-06-06 2015-12-10 The California Institute For Biomedical Research Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
US9710451B2 (en) * 2014-06-30 2017-07-18 International Business Machines Corporation Natural-language processing based on DNA computing
AU2015303825B2 (en) * 2014-08-15 2021-01-14 Baylor College Of Medicine Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US20180264080A1 (en) * 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
JP6913030B2 (ja) 2015-05-18 2021-08-04 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
US10388404B2 (en) 2015-10-27 2019-08-20 International Business Machines Corporation Using machine-learning to perform linear regression on a DNA-computing platform
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
BR112018014810A2 (pt) 2016-01-22 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
CN116425879A (zh) 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
WO2018013483A1 (en) * 2016-07-11 2018-01-18 The California Institute For Biomedical Research Kv1.3 channel blocking peptides and uses thereof
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
CN120518763A (zh) 2019-04-01 2025-08-22 诺和诺德股份有限公司 针对利拉鲁肽的抗体及其用途
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
TW202542185A (zh) * 2023-12-08 2025-11-01 美商健生生物科技公司 具有增強的效應功能之ｇｐｒｃ５ｄ抗體及其用途
WO2025184315A1 (en) 2024-02-29 2025-09-04 Amgen Inc. Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies
WO2025209486A1 (en) 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof
WO2025244108A1 (ja) * 2024-05-23 2025-11-27 国立大学法人 東京大学 新規蛍光標識方法
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
KR100195632B1 (ko) 1988-07-23 1999-06-15 스티븐 조지 가랜드 펩티드 및 dna 배열
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FI92507C (fi) 1991-12-19 1994-11-25 Valto Ilomaeki Menetelmä ja laite maaperään pakotettavien putkien ohjaamiseksi
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
SG55079A1 (en) 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
WO1995022992A2 (en) 1994-02-23 1995-08-31 Chiron Corp Method and compositions for increasing the serum half-life of pharmacologically active agents
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1998023639A2 (en) * 1996-11-27 1998-06-04 University Of Florida ShK TOXIN COMPOSITIONS AND METHODS OF USE
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ATE307829T1 (de) 1996-12-26 2005-11-15 Suntory Ltd Skorpion-spezifische neuropeptide
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
DE69940785D1 (de) 1998-11-20 2009-06-04 Fuso Pharmaceutical Ind Proteinexpressionsvektor und benutzung desselbigen
CA2368068A1 (en) 1999-03-18 2000-09-21 Steven M. Ruben 27 human secreted proteins
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
RU2317999C2 (ru) 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
PL2382990T3 (pl) 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI1680140T1 (sl) 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CN101072577B (zh) * 2004-10-07 2013-12-18 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
CA2587463A1 (en) 2004-11-16 2006-11-30 Avidia Research Institute Protein scaffolds and uses therof
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2007009018A2 (en) 2005-07-13 2007-01-18 Amgen Mountain View Inc. Il-6 binding proteins
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
ES2905054T3 (es) * 2006-11-01 2022-04-06 Ventana Med Syst Inc Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
JP5622397B2 (ja) 2007-03-12 2014-11-12 エスバテック− ア ノバルティス カンパニー エルエルシー 一本鎖抗体の配列に基づく操作および最適化
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US20090203038A1 (en) 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
AU2009227050A1 (en) 2008-03-20 2009-09-24 Csl Behring Gmbh The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
JP6101489B2 (ja) 2010-01-28 2017-03-22 アブ バイオサイエンシズ インコーポレイテッド 親和性が低下した抗体およびそれを作製する方法
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014011793; ＧＳ Ｇｅｎｄｅｈ ｅｔ ａｌ: 'Ａ Ｎｅｗ Ｐｏｔａｓｓｉｕｍ Ｃｈａｎｎｅｌ Ｔｏｘｉｎ ｆｒｏｍ ｔｈｅ Ｓｅａ Ａｎｅｍｏｎｅ Ｈｅｔｅｒａｃｔｉｓ ｍａｇｎｉｆｉｃａ： Ｉｓｏｌａｔｉｏｎ， ｃＤＮＡ Ｃｌｏｎｉｎｇ， ａ' Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３６, 1997, ｐ．１１４６１-１１４７１ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505639A (ja) * 2013-01-25 2016-02-25 ヤンセン バイオテツク，インコーポレーテツド Ｋｖ１．３アンタゴニスト及び使用方法
US10179808B2 (en) 2013-01-25 2019-01-15 Janssen Biotech, Inc. Kv1.3 antagonists and methods of use
JP2018521062A (ja) * 2015-06-29 2018-08-02 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
JP2021180671A (ja) * 2015-06-29 2021-11-25 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
JP7193590B2 (ja) 2015-06-29 2022-12-20 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
WO2018135598A1 (ja) * 2017-01-19 2018-07-26 国立大学法人 東京大学 新規蛍光標識方法
JPWO2018135598A1 (ja) * 2017-01-19 2019-12-12 国立大学法人 東京大学 新規蛍光標識方法
JP7178701B2 (ja) 2017-01-19 2022-11-28 国立大学法人 東京大学 新規蛍光標識方法
JP2023019170A (ja) * 2021-07-28 2023-02-09 株式会社三協 錠剤用崩壊剤及びこれを利用した錠剤
JP7458085B2 (ja) 2021-07-28 2024-03-29 株式会社三協 錠剤用崩壊剤及びこれを利用した錠剤

Also Published As

Publication number Publication date
MX2011009798A (es) 2011-12-08
AU2010226392B9 (en) 2014-05-22
EP3385279A1 (en) 2018-10-10
EP2408814A2 (en) 2012-01-25
MX2011009797A (es) 2012-01-12
EP3385279B1 (en) 2020-02-26
EP2432488A4 (en) 2014-01-08
US20120195879A1 (en) 2012-08-02
WO2010108154A2 (en) 2010-09-23
EP2408814A4 (en) 2013-01-09
US20150044236A1 (en) 2015-02-12
AU2010226391C1 (en) 2016-11-24
AU2010226392A1 (en) 2011-10-06
AU2010226392B2 (en) 2014-04-03
AU2010226391B2 (en) 2013-11-14
JP2015120706A (ja) 2015-07-02
US9562107B2 (en) 2017-02-07
CA2755336A1 (en) 2010-09-23
CA2755336C (en) 2015-07-14
MX347295B (es) 2017-04-20
AU2010226391A1 (en) 2011-10-13
US9562108B2 (en) 2017-02-07
US10189912B2 (en) 2019-01-29
CA2755133A1 (en) 2010-09-23
WO2010108154A3 (en) 2011-03-03
MX347291B (es) 2017-04-17
JP6345832B2 (ja) 2018-06-20
CA2889453C (en) 2018-11-06
JP6173359B2 (ja) 2017-08-02
CA2889453A1 (en) 2010-09-23
WO2010108153A3 (en) 2010-11-18
CA3018235C (en) 2021-01-12
US20170190793A1 (en) 2017-07-06
CA3018235A1 (en) 2010-09-23
WO2010108153A2 (en) 2010-09-23
US20150044235A1 (en) 2015-02-12
EP2408814B1 (en) 2018-11-21
JP6609347B2 (ja) 2019-11-20
JP2012521197A (ja) 2012-09-13
JP2017163986A (ja) 2017-09-21
US8734796B2 (en) 2014-05-27
JP2018139609A (ja) 2018-09-13
EP2432488A2 (en) 2012-03-28
US20120121591A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
AU2010226392B2 (en) Selective and potent peptide inhibitors of Kv1.3
US9796766B2 (en) Potent and selective inhibitors of NAV1.3 and NAV1.7
US7820623B2 (en) Conjugated toxin peptide therapeutic agents
JP5220915B2 (ja) 延長された血液半減期を有するトキシンペプチド
US10344060B2 (en) Potent and selective inhibitors of Nav1.7
US9803019B2 (en) Carrier immunoglobulins and uses thereof
US9636418B2 (en) Potent and selective inhibitors of NAV1.7
NZ615242B2 (en) Potent and selective inhibitors of nav1.3 and nav1.7

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303